Recombinant Cynomolgus Monkey IFN-alpha/beta R1 Protein, CF

When Recombinant Cynomolgus Monkey IFN‑ alpha / beta R1 His-tags protein is immobilized at 10 µg/mL (100 µL/well), Recombinant Human IFN-A2 binds with an ED50 of 1-6 ug/mL.

2 μg/lane of Recombinant Cynomolgus Monkey IFN-alpha/beta R1 Protein, CF (Catalog # 10674-AB) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 80-100 kDa.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus Monkey IFN-alpha/beta R1 Protein, CF Summary

• Additional Information: His-tag
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinan Cynomolgus Monkey IFN‑ alpha / beta R1 His-tag protein is immobilized at 10 µg/mL (100 µL/well), Recombinant Human IFN-A2 binds with an ED₅₀ of 1-6 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived cynomolgus monkey IFN-alpha/beta R1 protein
  Ala23-Ile439, with a C-terminal 6-His tag
• Accession #: EHH61907.1
• N-terminal Sequence: Ala23 & Gly26
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 48 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 80-100 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus Monkey IFN-alpha/beta R1 Protein, CF

• alpha-type antiviral protein
• AVP
• beta-type antiviral protein
• CRF2-1
• Cytokine receptor class-II member 1
• Cytokine receptor family 2 member 1
• human interferon-alpha receptor (HuIFN-alpha-Rec)10IFRC
• IFN-alpha/beta R1
• IFN-alpha/beta receptor 1
• IFN-alpha-REC
• IFNAR
• IFNAR1
• IFN-aR1
• IFNBR
• IFNbR1
• IFN-bR1
• IFN-R-1
• interferon (alpha, beta and omega) receptor 1
• interferon alpha/beta receptor 1
• interferon-alpha/beta receptor alpha chain
• interferon-beta receptor 1
• Type I interferon receptor 1

Background

Interferon-alpha/beta receptor 1 (IFN-alpha / beta R1), also known as IFNAR1, is a member of the class II cytokine receptor family of proteins. These proteins form heterodimeric receptor complexes that mediate class II cytokine signals and subunits of the different receptor complexes are shared and serve multiple functions (1). Mature human IFN-alpha / beta R1 consists of an extracellular domain (ECD) with three tandem fibronectin type III repeats, a transmembrane segment, and a cytoplasmic domain (2). Within the ECD, human IFN-alpha / beta R1 shares 47% and 50% amino acid sequence identity with mouse and rat IFN-alpha / beta R1, respectively. Alternative splicing generates two additional isoforms that lack the transmembrane segment and either all or a portion of the cytoplasmic domain. IFN-alpha / beta R1, in association with IFN-alpha / beta R2, is required for propagating anti-microbial signal transduction triggered by the type 1 interferons such as IFN-alpha and IFN-beta (3, 4). IFN-alpha / beta R1 interacts very weakly or not at all with type 1 interferons and does not stably interact with IFN-alpha / beta R2. Ligands preferentially associate with IFN-alpha / beta R2, and this complex subsequently forms a stable ternary assembly with IFN-alpha / beta R1 (5-7). IFN-alpha / beta R1 also associates with IFN-gamma R2 even in the absence of IFN-gamma stimulation (3). IFN-alpha / beta R1 activation depends on tyrosine phoshorylation as well as palmitoylation of its cytoplasmic domain (8, 9). Rapid down-regulation of the receptor is accomplished by ligand‑dependent or -independent pathways (e.g. VEGF R signaling, TLR signaling, or cellular stress) which induce its serine phosphorylation, ubiquitination, and degradation (10-13).

1. Langer, J.A. et al. (2004) Cytokine Growth Factor Rev. 15:33.
2. Uze, G. et al. (1990) Cell 60:225.
3. Hwang, S.Y. et al. (1995) Proc. Natl. Acad. Sci. USA 92:11284.
4. Takaoka, A. et al. (2000) Science 288:2357.
5. Lamken, P. et al. (2004) J. Mol. Biol. 341:303.
6. Arduini, R.M. et al. (1999) Prot. Sci. 8:1867.
7. Kalie, E. et al. (2008) J. Biol. Chem. 283:32925.
8. Platanias, L.C. (2005) Nat. Rev. Immunol. 5:375.
9. Claudinon, J. et al. (2009) J. Biol. Chem. 284:24328.
10. Zheng, H. et al. (2011) Blood 118:4003.
11. Qian, J. et al. (2011) PLoS Pathogens 7:e1002065.
12. Bhattacharya, S. et al. (2010) J. Biol. Chem. 285:2318.
13. Bhattacharya, S. et al. (2011) J. Biol. Chem. 286:22069.

Bioinformatics

• Uniprot:
  • EHH61907.1()